Sinopharm Group Co. Ltd.

OTCPK:SHTD.F Stock Report

Market Cap: US$8.3b

Sinopharm Group Valuation

Is SHTD.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SHTD.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SHTD.F ($2.52) is trading below our estimate of fair value ($6.93)

Significantly Below Fair Value: SHTD.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SHTD.F?

Key metric: As SHTD.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SHTD.F. This is calculated by dividing SHTD.F's market cap by their current earnings.
What is SHTD.F's PE Ratio?
PE Ratio6.7x
EarningsCN¥8.65b
Market CapCN¥60.29b

Price to Earnings Ratio vs Peers

How does SHTD.F's PE Ratio compare to its peers?

The above table shows the PE ratio for SHTD.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.3x
HSIC Henry Schein
30.8x26.7%US$9.7b
CAH Cardinal Health
23.2x7.5%US$29.7b
PDCO Patterson Companies
11.2x8.4%US$1.9b
COR Cencora
32x14.6%US$48.3b
SHTD.F Sinopharm Group
6.7x4.5%US$64.8b

Price-To-Earnings vs Peers: SHTD.F is good value based on its Price-To-Earnings Ratio (6.7x) compared to the peer average (24.3x).

Price to Earnings Ratio vs Industry

How does SHTD.F's PE Ratio compare vs other companies in the US Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NEUE NeueHealth
1.4xn/aUS$39.39m
IDXG Interpace Biosciences
2.8xn/aUS$13.61m
FZMD Fuse Medical
1.5xn/aUS$5.79m
No more companies available in this PE range
SHTD.F 6.7xIndustry Avg. 24.4xNo. of Companies11PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SHTD.F is good value based on its Price-To-Earnings Ratio (6.7x) compared to the US Healthcare industry average (24.4x).

Price to Earnings Ratio vs Fair Ratio

What is SHTD.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SHTD.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SHTD.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SHTD.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.52
US$3.00
+19.0%
17.6%US$3.84US$1.91n/a15
Nov ’25US$2.59
US$3.00
+16.1%
17.6%US$3.84US$1.91n/a15
Oct ’25n/a
US$3.13
0%
17.1%US$3.95US$1.94n/a16
Sep ’25US$2.06
US$3.13
+52.0%
15.3%US$3.90US$2.19n/a16
Aug ’25n/a
US$3.37
0%
10.8%US$3.88US$2.70n/a16
Jul ’25n/a
US$3.39
0%
11.5%US$4.12US$2.69n/a16
Jun ’25US$2.70
US$3.41
+26.2%
10.8%US$4.15US$2.71n/a16
May ’25US$2.64
US$3.40
+28.7%
10.8%US$4.14US$2.70n/a16
Apr ’25US$2.61
US$3.47
+33.0%
10.0%US$4.12US$2.79n/a16
Mar ’25US$2.90
US$3.54
+22.1%
12.9%US$4.33US$2.63n/a15
Feb ’25US$2.70
US$3.53
+30.7%
12.9%US$4.34US$2.68n/a14
Jan ’25US$2.49
US$3.51
+40.8%
15.0%US$4.36US$2.45n/a14
Dec ’24US$2.50
US$3.57
+42.5%
17.5%US$4.78US$2.41n/a14
Nov ’24US$2.39
US$3.53
+48.2%
18.1%US$4.73US$2.39US$2.5913
Oct ’24US$2.92
US$3.66
+25.3%
16.3%US$4.74US$2.63n/a15
Sep ’24US$2.82
US$3.69
+30.9%
15.9%US$4.76US$2.64US$2.0615
Aug ’24US$3.07
US$3.70
+20.6%
17.5%US$4.64US$2.31n/a16
Jul ’24US$2.96
US$3.63
+22.8%
18.2%US$4.58US$2.30n/a16
Jun ’24n/a
US$3.65
0%
18.2%US$4.65US$2.33US$2.7016
May ’24US$3.63
US$3.59
-1.1%
17.7%US$4.76US$2.40US$2.6415
Apr ’24US$2.96
US$3.43
+15.8%
13.2%US$3.96US$2.41US$2.6115
Mar ’24US$2.75
US$2.95
+7.2%
20.7%US$3.92US$1.60US$2.9015
Feb ’24US$2.54
US$3.00
+17.9%
20.9%US$4.01US$1.63US$2.7015
Jan ’24US$2.53
US$3.00
+18.6%
20.2%US$3.94US$1.61US$2.4916
Dec ’23US$2.27
US$2.87
+26.4%
20.7%US$3.80US$1.55US$2.5015
Nov ’23US$1.92
US$2.83
+47.4%
20.6%US$3.75US$1.53US$2.3915

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.75

7D

0.05%

1Y

-16.6%

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.27

7D

-0.3%

1Y

22.3%

Sensus Healthcare

US$141.0m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

SRTS

US$8.60

7D

-3.3%

1Y

253.9%